Oral Oncolytics Play Vital Role in the Treatment of Neuroendocrine Tumors

With a growing focus on oral oncolytics across the oncology spectrum, Mei Ka Fong, PharmD, BCOP, said oral oncolytics have traditionally always been a major part of the treatment for neuroendocrine tumors.

In an interview with Pharmacy Times about her presentation at the North American Neuroendocrine Tumor Society (NANETS) 2021 neuroendocrine tumor (NET) Medical Symposium, Fong said the only exceptions to the widespread use of oral oncolytics for NETs are commonly used somatostatin analogue injections, which are administered once a month, and potential intravenous drugs for patients with poorly differentiated tumors.